Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Ramalingam on the Efficacy of Trastuzumab Deruxtecan in HER2+ NSCLC

February 2nd 2021

Suresh S. Ramalingam, MD, FASCO, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive non–small cell lung cancer.

Larotrectinib Elicits Early Clinical Activity in NTRK Fusion–Positive Lung Cancer

February 2nd 2021

February 2, 2021 — Larotrectinib was found to elicit high response rates, durable responses, and to extend survival benefit in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.

QoL, Efficacy Data Support Use of Frontline Lorlatinib as New Standard in ALK+ NSCLC

February 2nd 2021

February 2, 2021 - The time to treatment deterioration for symptoms such as cough, dyspnea, and pain in the chest was found to be comparable between treatment-naïve patients with ALK-positive non–small cell lung cancer who received lorlatinib versus crizotinib.

Virtual Prehabilitation Improves Activity Level, Exercise Capacity Prior to Lung Cancer Surgery

February 2nd 2021

February 2, 2021 - Virtual prehabilitation could potentially improve physical activity level and exercise capacity in patients with lung cancer before they undergo surgery for their disease.

Dr. Spigel Discusses Advances in Early-Stage Lung Cancer

February 1st 2021

David Spigel, MD, discusses advances in early-stage lung cancer treatment.

cfDNA Methylation Assay Allows for Early Lung Cancer Detection

February 1st 2021

February 1, 2021 — Targeted circulating tumor DNA methylation marker panels possess the potential for early blood-based detection of lung cancer with a high sensitivity and specificity.

Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC

February 1st 2021

In our exclusive interview, Dr. Sanborn and Dr. Gaffar share insight into the clincal and economic considerations for treatment in advanced NSCLC.

Ongoing Novel Immunotherapy Trial Builds on PACIFIC Benefits in Stage III NSCLC

February 1st 2021

Dan Costin, MD, discusses his strategies for patients with early-stage lung cancer and ongoing trials that could improve outcomes even further.

Sequist Calls 2020 a Banner Year in Lung Cancer, But Leaves Much to Be Desired

February 1st 2021

Lecia V. Sequist, MD, discusses some of the biggest advancements of 2020 in lung cancer.

Repotrectinib Elicits Early Responses in ROS1+ Metastatic NSCLC

January 31st 2021

January 31, 2021 - Repotrectinib, a next-generation ROS1 and TRK TKI, has demonstrated encouraging objective responses with acceptable tolerability in patients with ROS1 fusion–positive non–small cell lung cancer.

Atezolizumab Combo Demonstrates Survival Benefit for ES-SCLC in Maintenance Phase

January 31st 2021

January 31, 2021 - The latest data from the IMpower133 trial shows that maintenance therapy with atezolizumab plus carboplatin and etoposide improves overall survival and progression-free survival for patients with extensive stage small cell lung cancer.

Updated Data Show Durable Response for Tepotinib in MET exon 14 Skipping NSCLC

January 31st 2021

Tepotinib demonstrated durable clinical activity in patients with MET exon 14 skipping non‒small cell lung cancer.

Dr. Cho on the Updated Efficacy of Repotrectinib in TKI-Naïve ROS1+ NSCLC

January 31st 2021

Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.

Dr. Reck on the Efficacy of Maintenance Atezolizumab in ES-SCLC

January 31st 2021

Martin Reck, MD, PhD, discusses the efficacy of maintenance atezolizumab in patients with extensive-stage small cell lung cancer.

Neoadjuvant Atezolizumab Elicits Impressive Responses in Resectable NSCLC

January 30th 2021

January 30, 2021 - Neoadjuvant atezolizumab followed by surgery resulted in a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, as well as significant surgical outcomes with a high rate of R0 resection.

CONFIRM Data Push Nivolumab into Treatment Landscape for Relapsed Mesothelioma

January 30th 2021

January 30, 2021 - Data from the phase 3 CONFIRM trial support single-agent nivolumab as an effective treatment approach for patients with previously treated malignant mesothelioma.

Dr. Liu on Emerging Data With Novel ADCs in NSCLC

January 30th 2021

Stephen Liu, MD, discusses emerging research on antibody–drug conjugate in non–small cell lung cancer that were presented during the 2020 World Conference on Lung Cancer.

Dr. Velcheti on the Results of the CodeBreaK 100 Primary Analysis in KRAS G12C+ NSCLC

January 30th 2021

Vamsidhar Velcheti, MD, discusses the results from the primary analysis of the CodeBreaK 100, which examined sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

HRQoL Maintained With Adjuvant Osimertinib in EGFR+ NSCLC

January 30th 2021

January 29, 2021 - Health-related quality of life was maintained for patients with EGFR-positive non–small cell lung cancer who received treatment with adjuvant osimertinib versus placebo, with no clinically meaningful differences noted between study arms.

Pembrolizumab/Ipilimumab Combo Does Not Improve Survival, Shows Higher Toxicity in PD-L1+ NSCLC

January 30th 2021

January 29, 2021 - Pembrolizumab plus ipilimumab did not improve survival and had higher rates of toxicity versus pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer who had a PD-L1 tumor proportion score of 50% or greater, and did not harbor EGFR or ALK aberrations.